The Global Specialty Medical Chairs Market is estimated to reach a market value of US$6.8 bn by 2023

Increasing Geriatric Population to Drive Greater Uptake of Specialty Medical Chairs

The global specialty medical chairs market stood at US$3.80 bn in 2014 and the market is anticipated to progress at a CAGR of 6.5% between 2015 and 2023. The consistently rising geriatric population will be the primary growth driver for the global market in the coming years, states Transparency Market Research. However, the high cost of chairs and the option of refurbishing old ones is restraining this market to some degree. Though the cost of these chairs is a challenge to the market’s growth, it also presents an opportunity to the manufacturers to reduce the prices and tap into the needs of the price-conscious consumers in the market.

The growing investments in the healthcare sector, especially in the developing countries, are bound to increase the sales of specialty medical chairs, expects TMR. The introduction of technologically advanced chairs by players such as Invacare Corporation, Fresenius Medical Care, and Topcon Medical Systems, Inc. that offer customizations to cater to clinical complications of patients such as pregnancy, obesity, and cardiac problems amongst others, is also likely to create remarkable opportunities for the market. The global specialty medical chairs market is thus estimated to hold an opportunity worth US$6.75 bn by the end of 2023.

Obtain Report Details @

Supportive Regulatory Framework Supports Growing Demand for Specialty Medical Chairs in North America

North America held the largest share in the overall market, accounting for 43.1% of it in 2014. A sizeable base of ophthalmic, ENT, and dental clinics across countries in North America have kept the investment sentiment positive in this region. Furthermore, supportive reimbursement policies for wheelchairs and bariatric chairs have also helped this market to achieve a significant growth rate in North America. Between 2015 and 2023, the North America specialty medical chairs market is expected to show a CAGR of 6.8%.

Asia Pacific has been identified as the most attractive market for specialty medical chairs over the forecast period. The projected rise in the number of geriatrics and rising disposable incomes will be the underlining factors augmenting the specialty medical chairs market in Asia Pacific. Countries such as India, China, South Korea, and Singapore amongst others will be the focal points of the market’s growth.

Treatment and Rehabilitation Chairs to Witness Stable Demand

The increasing awareness about various medical conditions, growing access to medical assistance, and rising disposable incomes have expanded the end-user base for medical chairs. Against this backdrop, the investments and expenditure on treatment and rehabilitation chairs have soared in the past few years. The shifting preference of patients towards home health care and innovative business strategies adopted by players are also boosting the sales of specialty medical chairs, especially under the treatment and rehabilitation segment. The report states that the rehabilitation segment will exhibit a CAGR of 6.5% while the treatment chairs will have a CAGR of 8.1% between 2015 and 2023.

Fill the Form to Gain Deeper Insights on this Market @

Some of the key players operating the global specialty medical chairs market are Forest Dental Products, Inc., A-dec, Inc., Fresenius Medical Care, ACTEVAID, Inc., Invacare Corporation, and DentalEZ amongst others. To maintain a lead, companies will have to expand their distribution networks in the near future.


Global PAP and paracetamol market is driven by the significant increase in pharmaceutical investments

The global para-aminophenol (PAP) and paracetamol market has been growing due to the increasing cases of chronic diseases and conditions that need pain management solutions on a regular basis. About 80% of PAP produced worldwide is used for making paracetamol. Thus, the increasing consumption of the latter is directly impacting the growth of PAP market. Additionally, the growing awareness about the pain management solutions offered by paracetamol, which is essentially an effective analgesic, is a key factor boosting paracetamol consumption across the globe. The application of PAP (para-aminophenol) in several other areas such as for making dyes, rubber antioxidants, photo-developing agents, anti-ager, and other chemicals is also propelling the global market.

Transparency Market Research predicts that the opportunity in the global paracetamol market is expected to be worth US$1,049.7 mn by 2022 as against to US$900.2 mn in 2014. Meanwhile, the para-aminophenol (PAP) market, will reach US$709.2 mn by 2022 from US$452.7 mn in 2014. The emergence of India and China as leading chemical producers have also presented a score of opportunities to the overall market as PAP is expected to find increasing application in industries such as agro-chemicals, pharmaceuticals, and dyes amongst others. Players are also expected to tap into supportive infrastructural setup offered by emerging economies of Asia Pacific to increase and diversify their manufacturing capabilities.

Obtain Report Details @

North America to Account for 40% of Global Market by Volume by 2022

North America leads the global market, poised to account for 40% of the total market share in terms of volume by 2022. The region’s standing will be the result of a growing number of PAP manufacturers and a strong presence of state-of-art manufacturing units. The persistent efforts made to upgrade from chemical production to specialty chemical production in the region have also boosted the market in the recent past. Additionally, attempts to adhere to environmental regulations pertaining to manufacturing processes are also propelling the PAP market in North America.

Asia Pacific Market Flourishes with Advantage of Reduced Manufacturing Costs

TMR estimates that the Asia Pacific PAP market will exhibit a steady CAGR of 3.9% between 2014 and 2022, while the paracetamol market will rise at a CAGR of 1.9% during the same forecast period. Asia Pacific is expected to present abundant opportunities to the PAP and paracetamol market due to low labor costs, affordable research and development costs, a larger base of manpower, supportive infrastructure, and increasing trade volume due to an exponentially rising consumer base. These are the common denominators driving the consumption and production of PAP and paracetamol in emerging economies of China and India.

An influx of investments in chemicals and pharmaceuticals industry has built the perfect framework for the consumption of PAP in various agro-chemicals and dyes along with a range of pharmaceutical compositions. All of these aspects have resulted in reduced costs of final products in comparison to products manufactured in North America and other European regions. Thus, consumers are preferring Asian products over others, while manufacturers are shifting bases to indulge in cost-benefits offered by countries in Asia Pacific. Citing these reasons, analysts predict that Asia Pacific will emerge as a significant regional segment during the forecast period.

Fill the Form to Gain Deeper Insights on this Market @

Some of the leading players operating in the global PAP and paracetamol market are Mallinckrodt plc, Granules India, Angene International Limited, Haihang Industry Co., Ltd., Jinan Haohua Industry Co., Ltd., Parchem Fine & Specialty Chemicals, and Kemcolour International. Companies will strengthen their distribution channels to reach out to a wider audience to maintain their leadership in the overall market.

Global Outlook for Tissue Engineered Skin Substitutes Forecast to 2023 Illuminated by New Report

Tissue Engineered Skin Substitutes Market: Snapshot

The elderly are highly prone to contracting skin diseases such as various forms of ulcers due to their significantly reduced flow of blood and overall immunity against diseases. The number of geriatrics in all nations has been on the rise owing to multiple factors, and a rise in their number is a direct call to action for all related healthcare organizations, products, and services. This includes the tissue engineered skin substitute providers and makes the above the top driver for its market.

The number of patients suffering from skin diseases and ulcers is also increasing within younger demographics. The CDC, for instance, stated in 2015 that close to 900,000 people are affected by DVT per year. A large number of patients were additionally being diagnosed with venous diseases per year, further boosting the need for tissue engineered skin substitutes.

The market is, however, restrained by over competitiveness between local manufacturers and their globally prominent counterparts. The local manufacturers can offer tissue engineered skin substitutes at a much lower price than global ones, forcing the latter to drop prices and consequently their profit margins. This will affect the market’s rate of research and development in the long run.

These drivers and restraints are expected to converge to result in a CAGR of 17.2% for the global market of tissue engineered skin substitutes between 2015 and 2023. This market is expected to be valued at US$1.24 bn by the end of 2016, and US$3.87 bn by 2023.

Obtain Report Details @

North America Continues to Show Strong Demand for Tissue Engineered Skin Substitutes

The need for tissue engineered skin substitutes in North America has consistently been high over the past few years. It is expected to generate US$1.96 bn in revenue for tissue engineered skin substitute players by 2023. A key reason prompting the use of tissue engineered skin substitutes in North America is the very high prevalence of vascular diseases. The region holds an especially high proportion of the geriatric, diabetic, and obese demographics and thus requires tissue engineered skin substitutes to a higher degree than other major regions.

Europe is another key region for tissue engineered skin substitute players. This region shows a similarly high demand as that shown by North America, although at a smaller revenue cap. The highest demand for tissue engineered skin substitutes at the moment, however, comes from Asia Pacific. The revenue earned by tissue engineered skin substitute providers in this region is expected to progress at a CAGR of 18.3% from 2015 to 2023. Key reasons for the high proliferation of tissue engineered skin substitute players in Asia Pacific is the growing geriatric population in nations such as South Korea and Japan, along with the rapidly increasing investments made by governments into the market.

Fill the Form to Gain Deeper Insights on this Market @

Tissue Engineered Skin Substitutes to Find Increasing Demand in Treatment of Ulcers

Ulcers have consistently been the leading application segment for tissue engineered skin substitutes. By the end of 2023, nearly US$2.1 bn will be generated by tissue engineered skin substitute players through ulcer treatment alone. This segment is also expected to grow at a robust CAGR of 17.5% within 2015 and 2023.

The same applies to other skin disorders that are growing in prevalence across the globe. Most dermatology organizations such as the ADA have made their predictions, all of which point to a growing number of patients with skin disorders. The ADA, for instance, in 2013, released findings of a study that stated at least one in every five U.S. citizens will suffer from a skin disorder in their lifetime. This makes the development of dermatology solutions such as tissue engineered skin substitutes a matter of high concern.

The key manufacturers of tissue engineered skin substitutes include Acelity, Smith & Nephew, Molnlycke, ConVatec, Medtronic, and BSN Medical.

Patent Expiries to Severely Constrain Growth of Global Dyslipidemia Drugs Market until 2023, TMR Says

The global dyslipidemia market is anticipated to witness a decline of -10.3%. CAGR between 2015 and 2023. The negative growth rate is a result of the expiration of blockbuster drugs that have allowed the introduction of several generic drugs, available at cheaper prices than branded drugs. Owing to this reason, the global market is expected to reach a valuation of US$6.88 bn by 2023 as compared to US$17.85 bn in 2014. However, the market also has several opportunities to gain from and reach a positive growth rate in the near future. For instance, the high prevalence of obesity due to poor dietary habits, lack of exercise, and changing lifestyles are expected to present a wide range growth opportunities for the overall market in the near future.

Obtain Report Details @

Diabetes and Obesity Give a New Lease of Life to Dyslipidemia Drugs Market

The rising cases of diabetes, especially the growing number of type 2 diabetics, have presented the global dyslipidemia market with a lucrative opportunity. Research indicates that diabetics are likely to suffer from lipid abnormalities that will lead to a higher uptake of dyslipidemia drugs in the near future. In a bid to solve the health issues of an exponentially growing patient pool, several companies are investing in intensive research and development in strengthening their pipelines and discovering newer treatment options. Furthermore, commercialization of new classes of drugs will also provide this market a push in the upward direction.

Europe Experiences Minimal Loss in Revenues due to Higher Spending Power of Patients

The Europe dyslipidemia drugs market is expected to witness a relatively low decline (at a CAGR of -9.9%) over the forecast period of 2015 and 2023. The losses in this regional market will be mitigated by the high incidence of dyslipidemia here. Furthermore, the ability of patients to afford dyslipidemia drugs and supportive reimbursement policies are also expected to keep losses in this market in check to some degree.

Favorable government policies are also expected to help the Europe dyslipidemia market in the near future. Rising healthcare expenditure by dyslipidemia patients in countries such as Germany, France, and the U.K. are also anticipated to create a lucrative growth for sustained growth of the market in the coming years. By the end of forecast period, the Europe dyslipidemia drugs market will reach US$1,802.8 mn by 2023.

Fibric Acid and Omega-3 Fatty Acid Derivatives Segment Leads Overall Market

Amongst the various type of drug classes, the fibric acid and omega-3 fatty acid derivatives segment will witness the least decline at a -1.6% CAGR between 2015 and 2023. A growing number of prescriptions for drugs such as Epanova, Vascespa, and Lovaza will be the primary reason why this segment will be able to mitigate its loss. The government approvals for fibric acid and omega-3 fatty acid derivatives class of drugs have also bolstered the demand for dyslipidemia drugs in recent years. The report suggests that Fenofibrate drugs are the popularly prescribed fibric acid and omega-3 fatty acid derived drugs to patients with dyslipidemia.

However, the future of this segment is on unsteady ground as these major drugs are expected to lose their patents. For instance, fenofibrate-containing drugs such as Trilipix, Antara, Tricor, and others will gradually lose importance to generic drugs.

Fill the Form to Gain Deeper Insights on this Market @

Some of the leading players identified in this market are AstraZeneca plc., Merck & Co., Inc., Pfizer, Inc., Daiichi Sankyo Company, Limited, and Abbott Laboratories. The companies will continue to hold a strong presence due to their brand value and extensive goodwill in the market. Analysts state that new entrants must establish their foothold in the emerging market to profit from the large patient pool in developing countries of China and India and lower manufacturing costs.

Rising Prevalence of Diseases Prompts Progress in Canada Home Healthcare Market

Canada home healthcare market represents a wide range of home medical devices and services to support patients with chronic disease conditions. The risk and prevalence of chronic and lifestyle related diseases are constantly increasing in Canada which would drive the acceptance of home medical devices and services, consequently leading to the growth of the market. Moreover, changing demographics in Canada further supports the growth of Canada home healthcare market. Statistics Canada projected that around 5 million people in Canada were aged over 60– 65 years in 2011 and the number is expected to double in the next 25 years (10.4 million). Such change in demographics will shift a substantial portion of population to the higher risk level for illnesses that demand continuous medical intervention. Thus, this factor would in turn increase the utilization of home healthcare devices and services hence driving the market growth. Moreover, advancement in technologies, increasing sedentary lifestyle and growing preference for alternatives to hospital based long-term care also supports the Canada home healthcare market growth. However, high costs coupled with strict regulatory environment restraints the market growth. The Canada home healthcare market is estimated to be USD 10,449.1 million in 2013 and is expected to reach USD 18,939.9 million by 2020, growing at a CAGR of 8.9% from 2014 to 2020.

Obtain Report Details @

The Canada home healthcare market has been studied from three perspectives: by device types, by services and by provinces. Based on device types, the market has been segmented into four categories: diagnostic and monitoring devices, therapeutic home healthcare devices, home mobility assist devices and medical supplies. Among these, diagnostics and monitoring devices are accounted for the largest market, capturing over 30% of the total Canada home medical devices market in 2013. Efforts of the Canadian government to increase awareness about hypertension, diabetes and sleep apnea management through home monitoring drives the growth of diagnostics and monitoring devices segment. Moreover, home mobility assist devices market segment recorded the lowest revenue in 2013 owing to the low cost of market constituents such as cranes and crutches, walkers and rollators and others.

Based on services, the Canada home healthcare market is categorized into rehabilitation, telehealth and telemedicine, respiratory therapy, infusion therapy and unskilled home healthcare services. In 2013, unskilled home healthcare services market accounted for the largest market and is expected to dominate the market in future. Growing geriatric population coupled with increasing uptake of nonprofessional home care services in Canada helps this segment to grow consistently during the forecast period. Moreover, telehealth and telemedicine services only accounted for 2% revenue of the total home healthcare services market in 2013 but is expected to grow with the highest CAGR of around 11% during the forecast period from 2014 to 2020. Fundamental benefits availed from these services such as high cost-effectiveness, quality health care and access to health care services throughout rural and urban areas supports the growth of the market in Canada.

In terms of geographic distribution, the Canada home healthcare market has been segmented into four provinces i.e. Ontario, Quebec, Alberta and Rest of Canada. The Ontario home healthcare market in 2013 accounted for the largest market share due to high demand for home healthcare devices and services. Moreover, consistent rise in geriatric population and favorable government policies propels the growth of home healthcare market in Ontario. Followed by Ontario, Rest of Canada turned out to be the second largest market due to increasing number of obese population over the last few years. The Canada home healthcare market in Quebec is expected to grow at the highest CAGR of 9.2% from 2014 to 2020. The growth of this province is mainly attributed to the large population base and increasing incidence rate of chronic diseases.

Fill the Form to Gain Deeper Insights on this Market @

The Canada home healthcare market is fragmented in nature, having presence of large number of small scale and large scale home medical device and services providers. Some of the prominent home healthcare devices and service providers in the Canada home healthcare market are Johnson & Johnson, Omron Healthcare, 3M Healthcare, GM Healthcare, We Care Health Services, The Canadian Home Care Association, Home Care Ontario and others.

Iraq Healthcare (Surgical Procedures) Market Expected to Reach USD 530.3 Million by 2022

Iraq is one of the fastest growing economies in Middle East and North Africa (MENA) attributed by the flourishing oil sector that is helping the domestic government to improve health care services. The Iraq health care system is managed by mixed initiatives of public and private sector; wherein the public sector covers approximately 75% of all health care facilities, and the private sector represents the remaining 25%. Iraq has improved its health care system after years of war. The booming petroleum industry is helping the Government of Iraq to invest in improving health care services and develop medical infrastructure. Furthermore, the burden of non-communicable diseases is increasing significantly, which has created a significant demand for medical equipment and services in Iraq. This industry assessment focuses on understanding the growth prospects and current situation of various surgical procedures that are major applications of medical devices.

Obtain Report Details @

Among the major surgical procedures considered to be performed in the country, that include cardiac procedures, general surgeries, orthopedic surgeries, neurosurgeries and reconstructive surgeries; cardiac procedures emerged as the segment leader in terms of revenue in 2013. The substantiating factors behind such rapid growth of the segment are rise in prevalence of diabetes population susceptible to cardiovascular diseases and increasing base of target patient population requiring surgical procedures for their survival. According to the Iraqi Diabetes Association (IDA), there were around 1.2 million cases of diabetes in Iraq in 2014. Approximately 387 million people suffer from diabetes globally, of these more than 37 million people are from MENA. IDA also estimated that this number would increase to 68 million by 2035. Consequently, the rise in prevalence of diabetes population would lead to increase in cardiovascular diseases in Iraq. Other risk factors associated with cardiovascular diseases such as early onset hypertension, dyslipedemia, and obesity also contribute significantly towards increasing the overall CVD burden in Iraq. Thus, with the increase in number of cardiovascular patients and stable industry condition in Iraq, the flourishing healthcare industry trend of the country is expected to continue in the near future.

Fill the Form to Gain Deeper Insights on this Market @

Iraq healthcare industry is highly fragmented in nature, due to the presence of many international as well as domestic market players including distributors. However, few multinational market players such as Siemens Healthcare, Phillips Healthcare, and Medtronic plc, among others dominate the medical device industry in Iraq. Other players (including manufacturers and distributors) operating in the industry include Rudolf Riester GmbH, Minas Company, Ismailiya Medical Co., Albanna Group, GE Healthcare, MAQUET and Stryker Corporation; that cumulatively accounted for a share of over 40% in 2013. The market leadership of such players was attributed to several factors such as commercial availability of products, superior distribution channels, and demand satisfying supply capabilities.

X-ray Market is driven by presence of high geriatric population suffering from a range of respiratory disorders

Presently, the global market for X-ray systems and technologies is witnessing steady growth due to high prevalence and increasing incidence of cardiovascular, respiratory, gastrointestinal, and genitourinary, and several other disorders. Additionally, the global aging population and commercialization of new, improved and technologically advanced X-ray systems would boost demand, which would in turn fuel the growth of the X-ray market. New and advanced X-ray systems increasingly find applications in breast cancer imaging, detection of tumor outgrowths, and several other chronic disorders and diseases. Demand for advanced systems is rapidly rising due to the need for early diagnosis to ensure effective treatment and/or management of the disease. Recent technological advancements in the diagnostics industry has led to the introduction of several advanced X-ray systems such as mobile and handheld digital systems, direct digital radiography systems, direct & indirect flat panel detection based systems, and CMOS and CCD based digital systems.

Obtain Report Details @

Stationary or fixed X-ray systems held the largest share of 60.1% of the global X-ray market in 2013. Stationary or fixed X-ray systems have been in use for a long time — since the discovery of first X-ray based imaging and diagnostic systems — in developed as well as less developed nations in the world. This is due to portable systems, especially handheld X-ray systems, were launched recently in the global market. However, portable systems are expected to witness high growth rate during the forecast period, and would outperform the stationary X-ray systems segment by 2022. Hospitals, diagnostic laboratories and health care professionals have started installing and using several portable especially mobile systems globally as these systems offer portability and ease of use over stationary systems particularly for bedside imaging or home health care. Based on X-ray technologies, the digital X-ray systems segment held the largest share of 69.1%, followed by the analog systems segment in the global X-ray market in 2013. The computed radiography systems sub-segment held the largest share of the digital X-ray systems segment in 2013. However, the direct digital radiography systems segment is expected to register fastest growth during the forecast period and outperform the CR systems segment by 2022. This is majorly due to introduction and increased acceptance of advanced direct digital X-ray systems that offer several advantages over traditional systems such as low exposure to harmful X-rays, better image quality, and less time consumption.

According to World Health Organization (WHO) estimates, cardiovascular diseases accounted for around 17.3 million deaths in 2008, and the number is likely to increase to 23.3 million deaths each year by 2030. The low to middle income countries are the largest affected regions, accounting for 80% of all the deaths due to cardiovascular diseases across the world. According to WHO estimates, over 9 million people were suffering from tuberculosis globally in 2013. The number of TB cases increased by 4.7% from 8.6 million in 2012 to 9 million in 2013. The total number of deaths due to TB also increased by 15% from 1.3 million in 2012 to 1.5 million in 2013. According to WHO estimates, around 60% to 90% school children and 80% to 90% adults (age group: 19 – 34) suffer from dental cavities. Moreover, the global incidence rate of oral cancer ranges between one to ten cases per 100,000 individuals. At present, several X-ray technologies are increasingly being used for early detection of several chronic diseases and disorders to ensure effective diagnosis and treatment. However, high cost of advanced digital systems and implementation of legal provisions (e.g. affordable care act) that promote cost containment/cost cutting strategies could have a negative impact on the growth of the market in the near future. Moreover, presence of large underserved population in most of the emerging economies of the world would continue to provide future opportunities for the growth of the market during the forecast period.

North America held the largest share of 34.6% of the global X-ray market in 2013, followed by Asia Pacific and Europe. North America comprises the developed economies of the U.S. and Canada that have a large number of elderly individuals suffering from various cardiovascular, orthopedic, genitourinary, and abdominal diseases and disorders. Hence, rising occurrence of various disorders along with high awareness and affordability among people and well established health care infrastructure in the region increases demand for advanced X-ray systems. However, Asia Pacific is expected to register the fastest growth during the forecast period from 2014 to 2022 due to rapid growth expectation of this market in countries such as China and India. The key factor attributed to the high growth of the market in the region is the presence of high geriatric population suffering from a range of respiratory, cardiovascular, gastrointestinal, and genitourinary disorders requiring urgent diagnosis and effective treatment. Other factors include rising government support, increasing awareness and affordability, and corresponding demand for advanced X-ray systems across major economies in the region.

Fill the Form to Gain Deeper Insights on this Market @

Agfa-Gevaert N.V., Canon, Inc., Carestream Health, Inc., Fujifilm Holdings Corporation, GE Healthcare, Hologic, Inc., Hitachi Medical Corporation, Konica Minolta, Inc., Shimadzu Corporation, PerkinElmer, Inc., Philips Healthcare, Siemens Healthcare, Toshiba Corporation, and Varian Medical Systems, Inc. are the major players operating in the global X-ray market. Most of these players constantly innovate and develop technologically advanced and/or improved X-ray systems/technologies to maintain their position in the global market.